anti-TRBC1-SG3249

**anti-TRBC1-SG3249** is an antibody-drug conjugate (ADC) designed for selective targeting of T-cell cancers, specifically T-cell leukemias and lymphomas that express the TRBC1 constant region of the T-cell receptor beta chain. The ADC consists of an antibody that targets the TRBC1 epitope, conjugated via a cleavable linker to SG3249, a potent cytotoxic agent from the pyrrolobenzodiazepine (PBD) dimer class. Upon binding to TRBC1-expressing cells, the ADC is internalized and the SG3249 payload is released by intracellular cathepsin cleavage, causing DNA crosslinking and death of the malignant T cell. This targeted approach spares TRBC2-positive normal T cells, aiming to reduce immunosuppression while selectively eradicating cancer cells. The drug was developed in response to the challenge of treating T-cell cancers without causing severe immune deficiency, and has demonstrated curative potential in mouse models. The main developer is Johns Hopkins University, with collaboration ongoing for industry-led early-phase clinical trials[1][2][3][4][5][7].

Other names

anti-TRBC1–SG3249